These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35368895)

  • 1. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
    Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
    J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer.
    Yin Y; Yang H; Liu Z; Tan J; Zhu C; Chen M; Zhou R; Wang L; Qian J
    Cancer Manag Res; 2020; 12():13479-13487. PubMed ID: 33408520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study.
    Dai L; Gao T; Guo R; Chen Y; Wang J; Zhou S; Tang Y; Chen D; Huang S
    Neoplasia; 2024 Oct; 56():101029. PubMed ID: 39024777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
    Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
    BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
    Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
    Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
    Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
    Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
    Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
    Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
    Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
    Dai S; Zhang Y; Tan X; Luo F; Yan X
    Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
    Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
    Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
    Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
    Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.
    Jin N; Xu Y; Wang S; Sun C; Yan X; Yang F; Liang Y; Chen W; Huang X
    Cancer Pathog Ther; 2024 Jan; 2(1):31-37. PubMed ID: 38328709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
    Yang Y; Yang G; Li W; Hao X; Zhang S; Ai X; Lei S; Xu H; Wang Y
    Thorac Cancer; 2023 Nov; 14(33):3275-3281. PubMed ID: 37740599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.
    Liu J; Sun X; Du Q; Yao J; Dai M; Cheng Q; Xu H; Li Y; Liu X; Zhang M; Zhou Y; Yang Y
    Breast Cancer (Dove Med Press); 2022; 14():491-504. PubMed ID: 36575687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study.
    Zhang X; Li Z; Han L; Lv Z; Teng Y; Cui X; Zhou C; Wu H; Fang W; Xu L; Zhao S; Song C; Zheng Y; Gao T; Li M
    Onco Targets Ther; 2022; 15():1067-1078. PubMed ID: 36199295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
    Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
    MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.